CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

Cytokinetics (CYTK) provided guidance for corporate milestones expected to occur in 2025. Expected 2025 Milestones: Cardiac Muscle Programs: Aficamten: Advance go-to-market strategies and prepare ...

It might be easier to make sense of the recent fatal shooting of an insurance CEO, an act with ominous overtones about health care costs and insurance coverage, if any one aspect of health-care ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference ...

Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare ... release. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P.

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P.

Here are this week’s local business expansions, milestones and awards. EXPANDING University of Missouri Health Care’s Physician and Health Professional Wellness Program will offer statewide ...